TerminatedPhase 2NCT02855359
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seagen Inc.
- Principal Investigator
- Juan Pinelli, PA-C, MMSc.Seagen Inc.
- Intervention
- denintuzumab mafodotin(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2018
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Saint Bernards Cancer Center, Jonesboro, Arkansas, United States
- City of Hope, Duarte, California, United States
- Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
- Pacific Hematology Oncology Associates, San Francisco, California, United States
- University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States
- Poudre Valley Hospital Harmony Campus, Fort Collins, Colorado, United States
- Central Georgia Cancer Care, Macon, Georgia, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Montgomery Cancer Center, Mount Sterling, Kentucky, United States
- Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02855359 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.